logo

Corvus Pharmaceuticals, Inc. (CRVS)



Trade CRVS now with
  Date
  Headline
1/28/2019 4:09:21 PM Corvus Pharmaceuticals Appoints Linda Grais To Board Of Directors
6/28/2018 8:39:07 AM Corvus Reports Publication Of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity
4/26/2018 8:38:06 AM Corvus Pharma Begins Phase 1/1b Clinical Trial Of CPI-006 In Patients With Advanced Cancer
3/8/2018 9:07:13 AM Corvus Prices Public Offering Of 7.06 Mln Shares At $8.50 Per Share
2/1/2018 8:39:15 AM Corvus Announces Presentation Of New Data From Preclinical Study Of Novel T-Cell Signaling Pathway Inhibitor
6/5/2017 8:41:02 AM Corvus Announces Interim Safety And Efficacy Results From The Renal Cell Carcinoma And Non-small Cell Lung Cancer
4/4/2017 10:38:14 AM Corvus Pharmaceuticals Announces Interim Results From Ongoing Phase 1/1b Study
3/10/2017 8:08:22 AM Corvus Q4 Net Loss $11.1 Mln Vs. Loss $6.0 Mln Prior Year
1/10/2017 8:39:42 AM Corvus Expands Renal Cell Carcinoma Cohort In Ongoing Phase 1/1b Study Of Lead Checkpoint Inhibitor CPI-444
1/3/2017 4:11:45 PM Corvus Pharmaceuticals Names Ian Clark To Board Of Directors
11/11/2016 7:10:37 AM Corvus Pharmaceuticals Announces Preliminary Phase 1/1b Clinical Data With Lead Checkpoint Inhibitor CPI-444